Zinecard, Savene(dexrazoxane)
Dexrazoxane, Savene (dexrazoxane) is a small molecule pharmaceutical. Dexrazoxane was first approved as Zinecard on 1995-05-26. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat extravasation of diagnostic and therapeutic materials.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Dexrazoxane (discontinued: Totect, Zinecard)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cardioxane | unapproved drug for use in drug shortage | 2017-07-12 |
| dexrazoxane | ANDA | 2024-05-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1190 | Injection, dexrazoxane hydrochloride, per 250 mg |
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 2 | 10 | 4 | — | 1 | 17 |
| Leukemia | D007938 | — | C95 | 5 | 3 | 6 | — | 1 | 14 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 5 | 1 | 6 | — | 1 | 12 |
| Lymphoid leukemia | D007945 | — | C91 | 4 | 1 | 6 | — | — | 10 |
| Lymphoma | D008223 | — | C85.9 | 3 | 1 | 4 | — | 1 | 9 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | — | 5 | 2 | — | — | 7 |
| Osteosarcoma | D012516 | — | — | 2 | 2 | 1 | — | 2 | 7 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | 1 | 1 | 5 | — | — | 7 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 3 | 1 | — | — | 6 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | 2 | 1 | — | 1 | 5 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 3 | 1 | — | — | 1 | 5 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 2 | — | — | — | 3 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 2 | — | — | — | 3 |
| Rhabdomyosarcoma | D012208 | — | — | — | 3 | — | — | — | 3 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 1 | — | — | — | 2 |
| Preleukemia | D011289 | — | — | 1 | 1 | — | — | — | 2 |
| Blast crisis | D001752 | — | — | 1 | 1 | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Adenoid cystic carcinoma | D003528 | — | — | — | 1 | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 3 | — | — | — | 1 | 4 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 2 | — | — | — | — | 2 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 2 | — | — | — | — | 2 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 2 | — | — | — | — | 2 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | 1 | — | — | — | — | 1 |
Show 18 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 1 | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 1 | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dexrazoxane |
| INN | dexrazoxane |
| Description | (+)-dexrazoxane is a razoxane. It has a role as a chelator, an antineoplastic agent, a cardiovascular drug and an immunosuppressive agent. |
| Classification | Small molecule |
| Drug class | alpha-adrenoceptor antagonists (benzodioxane derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 |
Identifiers
| PDB | — |
| CAS-ID | 24584-09-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1738 |
| ChEBI ID | 50223 |
| PubChem CID | 71384 |
| DrugBank | DB00380 |
| UNII ID | 048L81261F (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Totect – Cumberland Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,605 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,181 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use